Custom Event Page 1 of 4 * required for saving Facility ID: Event #: *Patient ID:Social Security #: Secondary ID: Patient Name, Last: First: Middle: *Gender:

Slides:



Advertisements
Similar presentations
TREATMENT FOR SUPERIMPOSED PSEUDOMONAS AERUGINOSA INFECTION.
Advertisements

Facility ID:________________Event#_________________________ *Patient ID:_____________________ Social Security#: __ __ __ - __ __ - __ __ __ __ Secondary.
Edward L. Goodman, MD Core Faculty Hospital Epidemiologist June 27, 2013.
Restricted Antimicrobial Pager Restricted Antimicrobials Amikacin* Amphotericin, liposomal Amphotericin (Inhaled) Artemether/lumefantrine Atovaquone.
Antibiotics.
Enoch Omonge University of Nairobi
MANUAL on ALERT ORGANISM SURVEILLANCE
Antibiotic Choices for Infections which Require Hospitalization Rodolfo E. Bégué, MD Chief, Infectious Diseases Pediatrics, LSUHSC
A review and update of the CDS test CDS Workshop ASM 2009 Perth.
Plate 1a: Staphylococcus aureus resistant to penicillin (P0.5) only. Note the annular radius of the zone of inhibition of 9.5 mm around the cefoxitin (FOX.
Sorting Out Antibiotics: A systematic approach to antibiotic selection Kenneth Alexander, M.D., Ph.D. Associate Professor of Pediatrics and Microbiology.
BAD BUGS! Alfred DeMaria, Jr., M.D. Massachusetts Department of Public Health.
Gram-positive bacteria: Staphylococci
Gram Negative Gram Positive
COL Helen Viscount, PhD, D(ABMM) LTC Steven Mahlen, PhD, D(ABMM)
Culture and Sensitivity Helping the Infection Preventionist Interpret Antibiograms Walter Phillips, BS, MS, PhD Director of Microbiology TriStar Healthcare.
Facility ID#: *HCW ID#:Social Security #: Secondary ID#: HCW Name, Last: First: Middle: Street Address: City:State:Zip Code: Home Phone: ( ) Address:
Antibiotics 101 Puja Van Epps 1/20/14.
MDR Organisms in Holy Family Hospital Rawalpindi
Methods Revised Abstract Methods Results TP-271 is a Potent, Broad-Spectrum Fluorocycline with Activity Against Community-Acquired Bacterial Respiratory.
The Increasing Threat of Antibiotic Resistance Shira Doron, MD Assistant Professor of Medicine Division of Geographic Medicine and Infectious Diseases.
DHS/PP Antimicrobial Therapy David H. Spach, MD Professor of Medicine Division of Infectious Diseases University of Washington, Seattle.
Clinical Cases Beta-Lactam Answers. Case 1 What antibiotic would you recommend for intravenous therapy in a 40yo BM with a Staphylococcus aureus (MSSA)
INF 1 ® Life-Threatening Infections INF 1 ®. INF 2 ® Objectives Recognize predisposing conditions for infection Identify clinical manifestations of infection.
Do Physicians Find Our AST Reports As Confusing As We Do? Louis B. Rice, M.D. Louis Stokes Cleveland VA Medical Center and Case Western Reserve University.
Review of Antibiotics Zagorka Popovski, Pharm.D. Clinical Pharmacist, Intensive Care.
Zunilda Djanun*, Rudyanto S**, Yulia Rosa***, *Dept. Clinical Pharmacology FMUI/CMH, **ICU CMH, *** Dept. Clinical Microbiology FMUI.
Facility ID: Vaccination #: Healthcare Worker Demographics *HCW ID#: HCW Name, Last:First:Middle: *Gender:  F  M *Date of Birth: *Work Location: *Occupation:
Nebraska Public Health Laboratory 2008 CLSI M100-S18 update Paul D. Fey, Ph.D. Associate Professor/Associate Director Josh Rowland, M.T. (ASCP) State Training.
Panton-Valentine Leukocidin (PVL) is a toxin that destroys white blood cells and is a virulence factor in some strains of Staphylococcus aureus. PVL occurs.
© 2009 CSTS: The Cardiovascular Surgical Translational Study Using the Centers for Disease Control and Prevention’s National Healthcare Safety Network.
김의종(집필대표), 강정옥, 김미나, 김민중, 김성일, 이경원, 이도현, 이장호, 이남용, 이창규, 신종희, 장철훈, 최혜심
Common ID Syndromes March 2014.
Listing Antimicrobial Resistant Pathogens of Public Health Importance Implications for Drug Development Listing Antimicrobial Resistant Pathogens of Public.
Figure 1 shows the 10 most frequently isolated blood pathogens in these hospitals from 1997 through These species represent about 85% of blood isolates.
Antibiotics 101 A review of common infections and their treatment For others, like me, who have a mental block against all things related to antibiotics.
Impetigo The best topical agent is mupirocin; other agents, such as bacitracin and neomycin, are less effective. Patients who have numerous lesions or.
Hospital Acquired Pneumonia(HAP): is defined as a pneumonia which occurs after 48 hours of admission to hospital. Hospital Acquired Pneumonia(HAP): is.
 Community-acquired pneumonia (CAP) is a disease in which individuals who have not recently been hospitalized develop an infection of the lungs (pneumonia).
Let’s Really Implement Antimicrobial Stewardship Chris Gentry, Pharm.D., BCPS Clinical Coordinator and Clinical Specialist, Infectious Diseases Oklahoma.
Empirical Therapy for Ventilation Associated Pneumonia Azar. Hadadi Associate Professor of Infectious Diseases.
EARS-Net data on Antimicrobial Resistance in Ireland, Q3 2015
Facility ID:Event #: *Patient ID:Social Security #: Secondary ID: Patient Name, Last: First: Middle: *Gender: F M*Date of Birth: Ethnicity (specify):Race.
Dr. Laila M. Matalqah Ph.D. Pharmacology
Antibiotics: Selected Topics Steven Park, MD/PhD Director, Antimicrobial Stewardship Program Division of Infectious Diseases UCI Medical Center.
*Facility ID # : __________*Event # : __________ *Patient ID # : _____________ Social Security # : ___ ___ ___ - ___ ___ - ___ ___ ___ ___ Secondary ID.
*Facility ID:*Event #: *Patient ID:Social Security #: Secondary ID: Patient Name, Last: First: Middle: *Gender: F M*Date of Birth: Ethnicity (specify):Race.
* required for saving Tracking #: Facility ID:*Survey Year: Facility Characteristics *Ownership (check one): □ For profit □ Not for profit, including church.
*Facility ID # : _____________ *HCW ID # : _____________ Social Security # : ___ ___ ___ - ___ ___ - ___ ___ ___ ___ Secondary ID # : _____________ HCW.
Urinary Tract Infection (UTI) for LTCF Page 1 of 4 OMB No. xxxx-xxxx Exp. Date: xx-xx-xxxx * required for saving *Facility ID: Event #: *Resident ID:*Social.
Facility ID#: Med Admin#: Healthcare Worker Demographics *HCW ID#: *HCW Name, Last:First:Middle: *Gender:  F  M  Other *Date of Birth:// *Work Location:*Occupation:
Using Nursing Home Antibiograms To Improve Antibiotic Prescribing and Delivery Training Slides for Nursing Home Nurses Comprehensive Antibiogram Toolkit.
Assurance of Confidentiality: The information obtained in this surveillance system that would permit identification of any individual or institution is.
*Facility ID:*Event #: *Patient ID:Social Security #: Secondary ID: Patient Name, Last: First: Middle: *Gender: F M Other *Date of Birth: Ethnicity (specify):Race.
Facility ID:Procedure #: *Patient ID:Social Security #: Secondary ID: Patient Name, Last: First: Middle: *Gender: F M*Date of Birth: Ethnicity (specify):Race.
Principles of Medical Science Pharmacology Review
Facility Information: *Facility Name: __________________________________________________________________ *Main Telephone Number: ( ) ______-____________.
Therapeutics 3: Antibiotics Tutoring
Afaq R. Afridi, Tanveer Ahmad, Arshad Hussain and Abdul Samad.
Therapeutics III Tutoring February 10th, 2016
International Journal of Infectious Diseases
The Role of the Microbiology Laboratory in AMS programs
Antimicrobial Spectrum of Activity Visual Learning Exercises (“Flower Diagrams”) This work is licensed under the Creative Commons Attribution-NonCommercial-
Antibiotics sensitivity of microorganism causing nosocomial infections
Septicemia And Septic Shock Overview Almataria Teaching Hospital, Nasser Institute Cairo, Egypt Dr. Mamdouh Sabry MD. Ain Shams, PhD. France Consultant.
Metallo-β-lactamase-producing Pseudomonas aeruginosa in the Netherlands: the nationwide emergence of a single sequence type  A.K. Van der Bij, D. Van.
Strategies and Implementation: Pre-authorization vs. Post-prescription
19/ژانويه/17
Empiric antibiotic therapy
Presentation transcript:

Custom Event Page 1 of 4 * required for saving Facility ID: Event #: *Patient ID:Social Security #: Secondary ID: Patient Name, Last: First: Middle: *Gender: M F Other*Date of Birth: Ethnicity (specify):Race (specify): Event Details *Event Type:*Date of Event: Post Procedure Event: Yes NoDate of Procedure: NHSN Procedure Code:ICD-9-CM Procedure Code: *MDRO/CDI Infection Surveillance: NoDate Admitted to Facility: Location: Specific Event Type: Specify Criteria Used (check all that apply) Signs & Symptoms  Abscess  Apnea  Vomiting  Bradycardia  Redness  Cough  Dysuria  Fever  Acute onset of diarrhea (liquid stools for > 12 hours)  Purulent drainage or material  Pain or tenderness  New onset/change in sputum, increased secretions or increased suctioning  Localized swelling  Persistent microscopic or gross blood in stools  Wheezing, rales or rhonchi  Other evidence of infection found on direct exam, during surgery or by diagnostic testing +  Other signs and symptoms + Laboratory or Diagnostic Testing □ Positive culture □ Not cultured □ Positive blood culture □ Blood culture not done or no organisms detected in blood  Positive Gram stain when culture is negative or not done  >15 colonies cultured from IV cannula tip using semiquantitative culture method  Positive culture of pathogen  Positive culture of skin contaminant  Other positive laboratory tests  Radiographic evidence of infection Clinical Diagnosis  Physician diagnosis of this event type +  Physician institutes appropriate antimicrobial therapy + + Per specific event criteria Secondary Bloodstream Infection: Yes No Died: Yes NoEvent contributed to death? Yes No Discharge Date: ____/____/________*Pathogens Identified: Yes No *If Yes, specify on pages 2-3. Assurance of Confidentiality: The voluntarily provided information obtained in this surveillance system that would permit identification of any individual or institution is collected with a guarantee that it will be held in strict confidence, will be used only for the purposes stated, and will not otherwise be disclosed or released without the consent of the individual, or the institution in accordance with Sections 304, 306 and 308(d) of the Public Health Service Act (42 USC 242b, 242k, and 242m(d)).  Heat  Hypotension  Hypothermia  Lethargy  Nausea  Suprapubic tenderness

Custom Event OMB No Exp. Date: xx-xx-xxxx Page 2 of 4 Pathogen # Gram-positive Organisms _____ Staphylococcus coagulase-negative VANC S I R N _____ Enterococcus spp. (specify) __________ AMP S I R N CIPRO/LEVO/MOXI S I R N DAPTO S NS N DOXY/MINO S I R N GENTHL § S R N LNZ S I R N STREPHL § S R N TETRA S I R N TIG S NS N VANC S I R N _____ Enterococcus faecium AMP S I R N CIPRO/LEVO/MOXI S I R N DAPTO S NS N DOXY/MINO S I R N GENTHL § S R N LNZ S I R N QUIDAL S I R N STREPHL § S R N TETRA S I R N TIG S NS N VANC S I R N _____ Staphylococcus aureus CHLOR S I R N CIPRO/LEVO/MOXI S I R N CLIND S I R N DAPTO S NS N DOXY/MINO S I R N ERYTH S I R N GENT S I R N LNZ S R N OX/CEFOX/METH S I R N QUIDAL S I R N RIF S I R N TETRA S I R N TIG S NS N TMZ S I R N VANC S I R N Pathogen # Gram-negative Organisms _____ Acinetobacter spp. (specify) AMK S I R N AMPSUL S I R N AZT S I R N CEFEP S I R N CEFTAZ S I R N CIPRO/LEVO S I R N COL/PB S I R N GENT S I R N ___________ IMI S I R N MERO/DORI S I R N PIP/PIPTAZ S I R N TETRA/DOXY/MINO S I R N TMZ S I R N TOBRA S I R N _____ Escherichia coli AMK S I R N AMP S I R N AMPSUL/AMXCLV S I R N AZT S I R N CEFAZ S I R N CEFEP S I R N CEFOT/CEFTRX S I R N CEFTAZ S I R N CEFUR S I R N CEFOX/CETET S I R N CHLOR S I R N CIPRO/LEVO/MOXI S I R N COL/PB S I R N ERTA S I R N GENT S I R N IMI S I R N MERO/DORI S I R N PIPTAZ S I R N TETRA/DOXY/MINO S I R N TIG S I R N TMZ S I R N TOBRA S I R N _____ Enterobacter spp. (specify) AMK S I R N AMP S I R N AMPSUL/AMXCLV S I R N AZT S I R N CEFAZ S I R N CEFEP S I R N CEFOT/CEFTRX S I R N ___________ CEFTAZ S I R N CEFUR S I R N CEFOX/CETET S I R N CHLOR S I R N CIPRO/LEVO/MOXI S I R N COL/PB S I R N ERTA S I R N GENT S I R N IMI S I R N MERO/DORI S I R N PIPTAZ S I R N TETRA/DOXY/MINO S I R N TIG S I R N TMZ S I R N TOBRA S I R N _____ Klebsiella spp. (specify) AMK S I R N AMP S I R N AMPSUL/AMXCLV S I R N AZT S I R N CEFAZ S I R N CEFEP S I R N CEFOT/CEFTRX S I R N ___________ CEFTAZ S I R N CEFUR S I R N CEFOX/CETET S I R N CHLOR S I R N CIPRO/LEVO/MOXI S I R N COL/PB S I R N ERTA S I R N GENT S I R N IMI S I R N MERO/DORI S I R N PIPTAZ S I R N TETRA/DOXY/MINO S I R N TIG S I R N TMZ S I R N TOBRA S I R N (specify): _________________________ CDC (back), Rev 2, v6.4

Custom Event OMB No Exp. Date: xx-xx-xxxx Page 3 of 4 Pathogen # Gram-negative Organisms (continued) _____ Serratia marcescens AMK S I R N AMP S I R N AMPSUL/AMXCLV S I R N AZT S I R N CEFAZ S I R N CEFEP S I R N CEFOT/CEFTRX S I R N CEFTAZ S I R N CEFUR S I R N CEFOX/CETET S I R N CHLOR S I R N CIPRO/LEVO/MOXI S I R N COL/PB S I R N ERTA S I R N GENT S I R N IMI S I R N MERO/DORI S I R N PIPTAZ S I R N TETRA/DOXY/MINO S I R N TIG S I R N TMZ S I R N TOBRA S I R N _____ Pseudomonas aeruginosa AMK S I R N AZT S I R N CEFEP S I R N CEFTAZ S I R N CIPRO/LEVO S I R N COL/PB S I R N GENT S I R N IMI S I R N MERO/DORI S I R N PIP/PIPTAZ S I R N TOBRA S I R N _____ Stenotrophomonas maltophilia LEVO S I R N TETRA/MINO S I R N TICLAV S I R N TMZ S I R N Pathogen # Fungal Organisms _____Candida spp. ( specify) __________________ ANID S NS N CASPO S NS N FLUCO S S-DD R N FLUCY S I R N ITRA S S-DD R N MICA S NS N VORI S S-DD R N Pathogen # Other Organisms _____ Organism 1 ( specify) __________________ ____ Drug 1 S I R N ____ Drug 2 S I R N ____ Drug 3 S I R N ____ Drug 4 S I R N ____ Drug 5 S I R N ____ Drug 6 S I R N ____ Drug 7 S I R N ____ Drug 8 S I R N ____ Drug 9 S I R N _____ Organism 2 (specify) __________________ ____ Drug 1 S I R N ____ Drug 2 S I R N ____ Drug 3 S I R N ____ Drug 4 S I R N ____ Drug 5 S I R N ____ Drug 6 S I R N ____ Drug 7 S I R N ____ Drug 8 S I R N ____ Drug 9 S I R N _____ Organism 3 (specify) __________________ ____ Drug 1 S I R N ____ Drug 2 S I R N ____ Drug 3 S I R N ____ Drug 4 S I R N ____ Drug 5 S I R N ____ Drug 6 S I R N ____ Drug 7 S I R N ____ Drug 8 S I R N ____ Drug 9 S I R N Result Codes S = Susceptible I = Intermediate R = Resistant NS = Non-susceptible S-DD = Susceptible-dose dependent N = Not tested § GENTHL and STREPHL results: S=Susceptible/Synergistic and R=Resistant/Not Synergistic Drug Codes: AMK = amikacin AMP = ampicillin AMPSUL = ampicillin/sulbactam AMXCLV = amoxicillin/clavulanic acid ANID = anidulafungin AZT = aztreonam CASPO = caspofungin CEFAZ= cefazolin CEFEP = cefepime CEFOT = cefotaxime CEFOX= cefoxitin CEFTAZ = ceftazidime CEFTRX = ceftriaxone CEFUR= cefuroxime CETET= cefotetan CHLOR= chloramphenicol CIPRO = ciprofloxacin CLIND = clindamycin COL = colistin DAPTO = daptomycin DORI = doripenem DOXY = doxycycline ERTA = ertapenem ERYTH = erythromycin FLUCO = fluconazole FLUCY = flucytosine GENT = gentamicin GENTHL = gentamicin – high level test IMI = imipenem ITRA = itraconazole LEVO = levofloxacin LNZ = linezolid MERO = meropenem METH = methicillin MICA = micafungin MINO = minocycline MOXI = moxifloxacin OX = oxacillin PB = polymyxin B PIP = piperacillin PIPTAZ = piperacillin/tazobactam QUIDAL = quinupristin/dalfopristin RIF = rifampin STREPHL = streptomycin – high level test TETRA = tetracycline TICLAV = ticarcillin/clavulanic acid TIG = tigecycline TMZ = trimethoprim/sulfamethoxazole TOBRA = tobramycin VANC = vancomycin VORI = voriconazole CDC (back), Rev 2, v6.4

Custom Event OMB No Exp. Date: xx-xx-xxxx Page 3 of 4 Custom Fields Label ________________________ ___/___/___ ________________________ ___________ Label ________________________ ___/___/___ ________________________ ___________ Comments CDC (back), Rev 2, v6.4